DOCSLIB.ORG

10Th Anniversary of the Human Genome Project

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
10Th Anniversary of the Human Genome Project Grand Celebration: 10th Anniversary of the Human Genome Project Volume 3 Edited by John Burn, James R. Lupski, Karen E. Nelson and Pabulo H. Rampelotto Printed Edition of the Special Issue Published in Genes www.mdpi.com/journal/genes John Burn, James R. Lupski, Karen E. Nelson and Pabulo H. Rampelotto (Eds.) Grand Celebration: 10th Anniversary of the Human Genome Project Volume 3 This book is a reprint of the special issue that appeared in the online open access journal Genes (ISSN 2073-4425) in 2014 (available at: http://www.mdpi.com/journal/genes/special_issues/Human_Genome). Guest Editors John Burn University of Newcastle UK James R. Lupski Baylor College of Medicine USA Karen E. Nelson J. Craig Venter Institute (JCVI) USA Pabulo H. Rampelotto Federal University of Rio Grande do Sul Brazil Editorial Office Publisher Assistant Editor MDPI AG Shu-Kun Lin Rongrong Leng Klybeckstrasse 64 Basel, Switzerland 1. Edition 2016 MDPI • Basel • Beijing • Wuhan ISBN 978-3-03842-123-8 complete edition (Hbk) ISBN 978-3-03842-169-6 complete edition (PDF) ISBN 978-3-03842-124-5 Volume 1 (Hbk) ISBN 978-3-03842-170-2 Volume 1 (PDF) ISBN 978-3-03842-125-2 Volume 2 (Hbk) ISBN 978-3-03842-171-9 Volume 2 (PDF) ISBN 978-3-03842-126-9 Volume 3 (Hbk) ISBN 978-3-03842-172-6 Volume 3 (PDF) © 2016 by the authors; licensee MDPI, Basel, Switzerland. All articles in this volume are Open Access distributed under the Creative Commons License (CC-BY), which allows users to download, copy and build upon published articles even for commercial purposes, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. However, the dissemination and distribution of physical copies of this book as a whole is restricted to MDPI, Basel, Switzerland. III Table of Contents List of Contributors ................................................................................................................... V Preface ...................................................................................................................................... IX Erin Sandford and Margit Burmeister Genes and Genetic Testing in Hereditary Ataxias Reprinted from: Genes 2014, 5(3), 586-603 http://www.mdpi.com/2073-4425/5/3/586 ................................................................................. 1 Anke R. Hammerschlag, Tinca J. C. Polderman, Christiaan de Leeuw, Henning Tiemeier, Tonya White, August B. Smit, Matthijs Verhage and Danielle Posthuma Functional Gene-Set Analysis Does Not Support a Major Role for Synaptic Function in Attention Deficit/Hyperactivity Disorder (ADHD) Reprinted from: Genes 2014, 5(3), 604-614 http://www.mdpi.com/2073-4425/5/3/604 ............................................................................... 19 Thiviyani Maruthappu, Claire A. Scott and David P. Kelsell Discovery in Genetic Skin Disease: The Impact of High Throughput Genetic Technologies Reprinted from: Genes 2014, 5(3), 615-634 http://www.mdpi.com/2073-4425/5/3/615 ............................................................................... 29 Bjorn T. Adalsteinsson and Anne C. Ferguson-Smith Epigenetic Control of the Genome—Lessons from Genomic Imprinting Reprinted from: Genes 2014, 5(3), 635-655 http://www.mdpi.com/2073-4425/5/3/635 ............................................................................... 49 Gilberto Paz-Filho, Margaret C.S. Boguszewski, Claudio A. Mastronardi, Hardip R. Patel, Angad S. Johar, Aaron Chuah, Gavin A. Huttley, Cesar L. Boguszewski, Ma-Li Wong, Mauricio Arcos-Burgos and Julio Licinio Whole Exome Sequencing of Extreme Morbid Obesity Patients: Translational Implications for Obesity and Related Disorders Reprinted from: Genes 2014, 5(3), 709-725 http://www.mdpi.com/2073-4425/5/3/709 ............................................................................... 70 IV Stacey Pereira, Richard A. Gibbs and Amy L. McGuire Open Access Data Sharing in Genomic Research Reprinted from: Genes 2014, 5(3), 739-747 http://www.mdpi.com/2073-4425/5/3/739 ............................................................................... 87 Scott D. Boyd, Stephen J. Galli, Iris Schrijver, James L. Zehnder, Euan A. Ashley and Jason D. Merker A Balanced Look at the Implications of Genomic (and Other “Omics”) Testing for Disease Diagnosis and Clinical Care Reprinted from: Genes 2014, 5(3), 748-766 http://www.mdpi.com/2073-4425/5/3/748 ............................................................................... 96 Emma Duncan, Matthew Brown and Eileen M. Shore The Revolution in Human Monogenic Disease Mapping Reprinted from: Genes 2014, 5(3), 792-803 http://www.mdpi.com/2073-4425/5/3/792 ............................................................................. 115 Thomas Mikeska and Jeffrey M. Craig DNA Methylation Biomarkers: Cancer and Beyond Reprinted from: Genes 2014, 5(3), 821-864 http://www.mdpi.com/2073-4425/5/3/821 ............................................................................. 127 Grégory Caignard, Megan M. Eva, Rebekah van Bruggen, Robert Eveleigh, Guillaume Bourque, Danielle Malo, Philippe Gros and Silvia M. Vidal Mouse ENU Mutagenesis to Understand Immunity to Infection: Methods, Selected Examples, and Perspectives Reprinted from: Genes 2014, 5(4), 887-925 http://www.mdpi.com/2073-4425/5/4/887 ............................................................................. 173 William G. Newman and Graeme C. Black Delivery of a Clinical Genomics Service Reprinted from: Genes 2014, 5(4), 1001-1017 http://www.mdpi.com/2073-4425/5/4/1001 ........................................................................... 214 Donald Freed, Eric L. Stevens and Jonathan Pevsner Somatic Mosaicism in the Human Genome Reprinted from: Genes 2014, 5(4), 1064-1094 http://www.mdpi.com/2073-4425/5/4/1064 ........................................................................... 230 V List of Contributors Bjorn T. Adalsteinsson: Department of Genetics, University of Cambridge, Cambridge CB2 3EH, UK. Mauricio Arcos-Burgos: Genome Biology Department, The John Curtin School of Medical Research, The Australian National University, Garran Rd, building 131, Acton, Canberra, ACT 0200, Australia. Euan A. Ashley: Department of Medicine, Stanford University, Stanford, CA 94305, USA. Graeme C. Black: Manchester Centre for Genomic Medicine, Central Manchester University Hospitals, NHS Foundation Trust, Manchester, M13 9WL, UK. Cesar L. Boguszewski: Endocrine Division (SEMPR), Department of Internal Medicine, Federal University of Parana, Avenida Agostinho Leão Junior, 285-Alto da Glória. CEP 80030-110, Curitiba-PR, Brazil. Margaret C.S. Boguszewski: Endocrine Division (SEMPR), Department of Internal Medicine, Federal University of Parana, Avenida Agostinho Leão Junior, 285-Alto da Glória. CEP 80030-110, Curitiba-PR, Brazil. Guillaume Bourque: McGill University and Genome Quebec Innovation Center, Montréal, QC, H3A 1A4, Canada. Scott D. Boyd: Department of Pathology, Stanford University, Stanford, CA 94305, USA. Matthew Brown: University of Queensland Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, 37 Kent Road, Woolloongabba, Brisbane 4102, Queensland, Australia. Margit Burmeister: Molecular & Behavioral Neuroscience Institute/Departments of Human Genetics/Department of Psychiatry/Department of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA. Grégory Caignard: Complex Traits Group/Department of Human Genetics, McGill University, Montréal, QC H3G 0B1, Canada. Aaron Chuah: Genome Biology Department, The John Curtin School of Medical Research, The Australian National University, Garran Rd, building 131, Acton, Canberra, ACT 0200, Australia. Jeffrey M. Craig: Murdoch Childrens Research Institute, Royal Children's Hospital, Parkville, Victoria 3052, Australia; Department of Paediatrics, The University of Melbourne, Parkville, Victoria 3052, Australia. Christiaan de Leeuw: Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Neuroscience Campus Amsterdam, VU University Amsterdam, De Boelelaan 1085, 1081 HV Amsterdam, The Netherlands; Institute for Computing and Information Sciences, Radboud University Nijmegen, P.O. Box 9010, 6500 GL Nijmegen, The Netherlands. VI Emma Duncan: University of Queensland Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, 37 Kent Road, Woolloongabba, Brisbane 4102, Queensland, Australia; Department of Endocrinology and Diabetes, Royal Brisbane and Women's Hospital, Herston 4029, Queensland, Australia. Megan M. Eva: Department of Medicine/Complex Traits Group/Department of Human Genetics, McGill University, Montréal, QC H3G 0B1, Canada. Robert Eveleigh: McGill University and Genome Quebec Innovation Center, Montréal, QC, H3A 1A4, Canada. Anne C. Ferguson-Smith: Department of Genetics, University of Cambridge, Cambridge CB2 3EH, UK. Donald Freed: Program in Biochemistry, Cellular and Molecular Biology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Kennedy Krieger Institute, 707 N. Broadway, Baltimore, MD 21205, USA. Stephen J. Galli: Department of Microbiology and Immunology/Department of Pathology, Stanford University, Stanford, CA 94305, USA. Richard A. Gibbs: Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA. Philippe Gros: Department of Biochemistry/Complex Traits Group, McGill University, Montréal, QC H3G 0B1, Canada. Anke R. Hammerschlag: Department
Load more

Recommended publications
  • Cystatins in Immune System
    Journal of Cancer 2013, Vol. 4 45 Ivyspring International Publisher Journal of Cancer 2013; 4(1): 45-56. doi: 10.7150/jca.5044 Review Cystatins in Immune System Špela Magister1 and Janko Kos1,2 1. Jožef Stefan Institute, Department of Biotechnology, Ljubljana, Slovenia; 2. University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia. Corresponding author: Janko Kos, Ph. D., Department of Biotechnology, Jožef Stefan Institute, &Faculty of Pharmacy, University of Ljubljana, Slovenia; [email protected]; Phone+386 1 4769 604, Fax +3861 4258 031. © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. Received: 2012.10.22; Accepted: 2012.12.01; Published: 2012.12.20 Abstract Cystatins comprise a large superfamily of related proteins with diverse biological activities. They were initially characterised as inhibitors of lysosomal cysteine proteases, however, in recent years some alternative functions for cystatins have been proposed. Cystatins pos- sessing inhibitory function are members of three families, family I (stefins), family II (cystatins) and family III (kininogens). Stefin A is often linked to neoplastic changes in epithelium while another family I cystatin, stefin B is supposed to have a specific role in neuredegenerative diseases. Cystatin C, a typical type II cystatin, is expressed in a variety of human tissues and cells. On the other hand, expression of other type II cystatins is more specific. Cystatin F is an endo/lysosome targeted protease inhibitor, selectively expressed in immune cells, suggesting its role in processes related to immune response.
    [Show full text]
  • NSABB June-July 2005 Meeting Agenda
    First Meeting of the National Science Advisory Board for Biosecurity June 30 – July 1, 2005 Hyatt Regency Bethesda 7400 Wisconsin Ave. Bethesda, Maryland, 20814 USA Hotel Phone: 301-657-1234 Agenda Webcast: To watch the live webcast of the meeting, click here. The webcast can only be viewed when the meeting is in session at 8:00am-6:00pm on June 30 and at 8:00am-1:30pm on July 1 Eastern Time. You will need RealOne Player to view the webcast. If you do not already have RealOne Player on your computer, download here. Presentation slides: To access the following PowerPoint presentations, click on the presentation titles below. June 30, 2005 Opening Remarks and Swearing in Ceremony Elias Zerhouni, M.D. Director of the National Institutes of Health (NIH) Chair's Remarks and Agenda Overview Dennis L. Kasper, M.D. NSABB Chair Harvard Medical School Introduction of NSABB Members NSABB Structure and Operations Thomas Holohan, M.D. NSABB Executive Director, NIH Office of Biotechnology Activities Break Perspectives on Biosecurity in the Life Sciences NSABB Voting Members Impetus for NSABB: Enhancing Biosecurity on the Life Sciences Rajeev Venkayya, M.D. Special Assistant to the President, Senior Director for Biological and Chemical Defense White House Homeland Security Council Perspectives on Biosecurity in the Life Sciences NSABB Ex Officio Members Lunch Session I- The Development of Criteria for Identifying Dual Use Research and Research Results Introduction: Issues of Relevance to Criteria Development Arturo Casadevall, M.D., Ph.D. Professor of Medicine and of Microbiology & Immunology and Chief of Infectious Diseases Albert Einstein College of Medicine National Research Council Perspective: Experiments of Concern Ron Atlas, Ph.D.
    [Show full text]
  • Autoantibodies in Neurological Diseases
    Autoantibodies in neurological diseases Hu, Ri, Yo, Tr CV2 Amphiphysin Amphiphysin GM1 Ma/Ta CV2 Amphiphysin Cerebellum Intestine Hippocampus Control transfection CV2 GM2 SOX1 PNMAP 2 (MMa2/Ta) Zic4 PNMP A2 GM3G ITPR1 (MMa2/Ta) RiR CARP YoY RiR GD1G a GAD Hippocampus HEp-2 cells Cerebellum NMDAR (transf. cells) Recoverin HuH Titin Anti-Hu positive Anti-NMDA-receptor positive YoY GD1G b Recoverin Gangliosides MAG HuH GT1b SOS X1 Myelin Aquaporin-4 Titin GQ1G b MOG Zic4 VGKC (LGI1 + CASPR2) Cerebellum Intestine Cerebellum Control transfection NMDA receptors GAD65G AMPA receptors Tr (DNER) GABAB receptors DPPX Control CoC ntrol CoC ntrol IgLON5 Hippocampus HEp-2 cells Optic nerve AQP-4 (transf. cells) Glycine receptors Anti-Yo positive Anti-aquaporin-4 positive AChR Indirect immunofl uorescence EUROLINE Examples of relevant target antigens EUROIMMUN AG · Seekamp 31 · 23560 Lübeck (Germany) · Tel +49 451/5855-0 · Fax 5855-591 · [email protected] · www.euroimmun.com 2 Autoantibodies IIFT pattern Test systems Anti-Hu (ANNA-1*) IIFT: Granular fl uorescence of almost all neuronal nuclei on the substrates cerebellum and hippocampus. The Autoantibodies against basic, RNA- cell nuclei of the plexus myentericus (intestinal tissue) binding proteins of the neuronal cell are also positive. nuclei of the central and peripheral nervous system EUROLINE: Positive reaction of the recombinant Hu antigen (HuD). Associated diseases: encephalomyelitis, subacute sensory neuronopathy (Denny-Brown syndrome), autonomous neuropathy Associated tumours: small-cell lung carcinoma, Cerebellum Intestine neuroblastoma Anti-Ri (ANNA-2*) IIFT: Granular fl uorescence of almost all neuronal nuclei on the substrates cerebellum and hippocampus. The Autoantibodies against neuronal cell substrate intestine (plexus myentericus) shows no reac- nuclei of the central nervous system tion.
    [Show full text]
  • Neonatal Dermatology Review
    NEONATAL Advanced Desert DERMATOLOGY Dermatology Jennifer Peterson Kevin Svancara Jonathan Bellew DISCLOSURES No relevant financial relationships to disclose Off-label use of acitretin in ichthyoses will be discussed PHYSIOLOGIC Vernix caseosa . Creamy biofilm . Present at birth . Opsonizing, antibacterial, antifungal, antiparasitic activity Cutis marmorata . Reticular, blanchable vascular mottling on extremities > trunk/face . Response to cold . Disappears on re-warming . Associations (if persistent) . Down syndrome . Trisomy 18 . Cornelia de Lange syndrome PHYSIOLOGIC Milia . Hard palate – Bohn’s nodules . Oral mucosa – Epstein pearls . Associations . Bazex-Dupre-Christol syndrome (XLD) . BCCs, follicular atrophoderma, hypohidrosis, hypotrichosis . Rombo syndrome . BCCs, vermiculate atrophoderma, trichoepitheliomas . Oro-facial-digital syndrome (type 1, XLD) . Basal cell nevus (Gorlin) syndrome . Brooke-Spiegler syndrome . Pachyonychia congenita type II (Jackson-Lawler) . Atrichia with papular lesions . Down syndrome . Secondary . Porphyria cutanea tarda . Epidermolysis bullosa TRANSIENT, NON-INFECTIOUS Transient neonatal pustular melanosis . Birth . Pustules hyperpigmented macules with collarette of scale . Resolve within 4 weeks . Neutrophils Erythema toxicum neonatorum . Full term . 24-48 hours . Erythematous macules, papules, pustules, wheals . Eosinophils Neonatal acne (neonatal cephalic pustulosis) . First 30 days . Malassezia globosa & sympoidalis overgrowth TRANSIENT, NON-INFECTIOUS Miliaria . First weeks . Eccrine
    [Show full text]
  • Disease in a Murine Psoriasis Model Identification of Susceptibility Loci
    The Journal of Immunology Identification of Susceptibility Loci for Skin Disease in a Murine Psoriasis Model1 Daniel Kess,2*‡ Anna-Karin B. Lindqvist,2§ Thorsten Peters,*‡ Honglin Wang,* Jan Zamek,‡ Roswitha Nischt,‡ Karl W. Broman,¶ Robert Blakytny,† Thomas Krieg,‡ Rikard Holmdahl,§ and Karin Scharffetter-Kochanek3*‡ Psoriasis is a frequently occurring inflammatory skin disease characterized by thickened erythematous skin that is covered with silvery scales. It is a complex genetic disease with both heritable and environmental factors contributing to onset and severity. The ␤ CD18 hypomorphic PL/J mouse reveals reduced expression of the common chain of 2 integrins (CD11/CD18) and spontaneously develops a skin disease that closely resembles human psoriasis. In contrast, CD18 hypomorphic C57BL/6J mice do not demon- strate this phenotype. In this study, we have performed a genome-wide scan to identify loci involved in psoriasiform dermatitis under the condition of low CD18 expression. Backcross analysis of a segregating cross between susceptible CD18 hypomorphic PL/J mice and the resistant CD18 hypomorphic C57BL/6J strain was performed. A genome-wide linkage analysis of 94 pheno- typically extreme mice of the backcross was undertaken. Thereafter, a complementary analysis of the regions of interest from the genome-wide screen was done using higher marker density and further mice. We found two loci on chromosome 10 that were significantly linked to the disease and interacted in an additive fashion in its development. In addition, a locus on chromosome 6 that promoted earlier onset of the disease was identified in the most severely affected mice. For the first time, we have identified genetic regions associated with psoriasis in a mouse model resembling human psoriasis.
    [Show full text]
  • Characterization of Genomic Copy Number Variation in Mus Musculus Associated with the Germline of Inbred and Wild Mouse Populations, Normal Development, and Cancer
    Western University Scholarship@Western Electronic Thesis and Dissertation Repository 4-18-2019 2:00 PM Characterization of genomic copy number variation in Mus musculus associated with the germline of inbred and wild mouse populations, normal development, and cancer Maja Milojevic The University of Western Ontario Supervisor Hill, Kathleen A. The University of Western Ontario Graduate Program in Biology A thesis submitted in partial fulfillment of the equirr ements for the degree in Doctor of Philosophy © Maja Milojevic 2019 Follow this and additional works at: https://ir.lib.uwo.ca/etd Part of the Genetics and Genomics Commons Recommended Citation Milojevic, Maja, "Characterization of genomic copy number variation in Mus musculus associated with the germline of inbred and wild mouse populations, normal development, and cancer" (2019). Electronic Thesis and Dissertation Repository. 6146. https://ir.lib.uwo.ca/etd/6146 This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of Scholarship@Western. For more information, please contact [email protected]. Abstract Mus musculus is a human commensal species and an important model of human development and disease with a need for approaches to determine the contribution of copy number variants (CNVs) to genetic variation in laboratory and wild mice, and arising with normal mouse development and disease. Here, the Mouse Diversity Genotyping array (MDGA)-approach to CNV detection is developed to characterize CNV differences between laboratory and wild mice, between multiple normal tissues of the same mouse, and between primary mammary gland tumours and metastatic lung tissue.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Review Cutaneous Patterns Are Often the Only Clue to a a R T I C L E Complex Underlying Vascular Pathology
    pp11 - 46 ABstract Review Cutaneous patterns are often the only clue to a A R T I C L E complex underlying vascular pathology. Reticulate pattern is probably one of the most important DERMATOLOGICAL dermatological signs of venous or arterial pathology involving the cutaneous microvasculature and its MANIFESTATIONS OF VENOUS presence may be the only sign of an important underlying pathology. Vascular malformations such DISEASE. PART II: Reticulate as cutis marmorata congenita telangiectasia, benign forms of livedo reticularis, and sinister conditions eruptions such as Sneddon’s syndrome can all present with a reticulate eruption. The literature dealing with this KUROSH PARSI MBBS, MSc (Med), FACP, FACD subject is confusing and full of inaccuracies. Terms Departments of Dermatology, St. Vincent’s Hospital & such as livedo reticularis, livedo racemosa, cutis Sydney Children’s Hospital, Sydney, Australia marmorata and retiform purpura have all been used to describe the same or entirely different conditions. To our knowledge, there are no published systematic reviews of reticulate eruptions in the medical Introduction literature. he reticulate pattern is probably one of the most This article is the second in a series of papers important dermatological signs that signifies the describing the dermatological manifestations of involvement of the underlying vascular networks venous disease. Given the wide scope of phlebology T and its overlap with many other specialties, this review and the cutaneous vasculature. It is seen in benign forms was divided into multiple instalments. We dedicated of livedo reticularis and in more sinister conditions such this instalment to demystifying the reticulate as Sneddon’s syndrome. There is considerable confusion pattern.
    [Show full text]
  • The Capacity of Long-Term in Vitro Proliferation of Acute Myeloid
    The Capacity of Long-Term in Vitro Proliferation of Acute Myeloid Leukemia Cells Supported Only by Exogenous Cytokines Is Associated with a Patient Subset with Adverse Outcome Annette K. Brenner, Elise Aasebø, Maria Hernandez-Valladares, Frode Selheim, Frode Berven, Ida-Sofie Grønningsæter, Sushma Bartaula-Brevik and Øystein Bruserud Supplementary Material S2 of S31 Table S1. Detailed information about the 68 AML patients included in the study. # of blasts Viability Proliferation Cytokine Viable cells Change in ID Gender Age Etiology FAB Cytogenetics Mutations CD34 Colonies (109/L) (%) 48 h (cpm) secretion (106) 5 weeks phenotype 1 M 42 de novo 241 M2 normal Flt3 pos 31.0 3848 low 0.24 7 yes 2 M 82 MF 12.4 M2 t(9;22) wt pos 81.6 74,686 low 1.43 969 yes 3 F 49 CML/relapse 149 M2 complex n.d. pos 26.2 3472 low 0.08 n.d. no 4 M 33 de novo 62.0 M2 normal wt pos 67.5 6206 low 0.08 6.5 no 5 M 71 relapse 91.0 M4 normal NPM1 pos 63.5 21,331 low 0.17 n.d. yes 6 M 83 de novo 109 M1 n.d. wt pos 19.1 8764 low 1.65 693 no 7 F 77 MDS 26.4 M1 normal wt pos 89.4 53,799 high 3.43 2746 no 8 M 46 de novo 26.9 M1 normal NPM1 n.d. n.d. 3472 low 1.56 n.d. no 9 M 68 MF 50.8 M4 normal D835 pos 69.4 1640 low 0.08 n.d.
    [Show full text]
  • Review Article PTEN Gene: a Model for Genetic Diseases in Dermatology
    The Scientific World Journal Volume 2012, Article ID 252457, 8 pages The cientificWorldJOURNAL doi:10.1100/2012/252457 Review Article PTEN Gene: A Model for Genetic Diseases in Dermatology Corrado Romano1 and Carmelo Schepis2 1 Unit of Pediatrics and Medical Genetics, I.R.C.C.S. Associazione Oasi Maria Santissima, 94018 Troina, Italy 2 Unit of Dermatology, I.R.C.C.S. Associazione Oasi Maria Santissima, 94018 Troina, Italy Correspondence should be addressed to Carmelo Schepis, [email protected] Received 19 October 2011; Accepted 4 January 2012 Academic Editors: G. Vecchio and H. Zitzelsberger Copyright © 2012 C. Romano and C. Schepis. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. PTEN gene is considered one of the most mutated tumor suppressor genes in human cancer, and it’s likely to become the first one in the near future. Since 1997, its involvement in tumor suppression has smoothly increased, up to the current importance. Germline mutations of PTEN cause the PTEN hamartoma tumor syndrome (PHTS), which include the past-called Cowden, Bannayan- Riley-Ruvalcaba, Proteus, Proteus-like, and Lhermitte-Duclos syndromes. Somatic mutations of PTEN have been observed in glioblastoma, prostate cancer, and brest cancer cell lines, quoting only the first tissues where the involvement has been proven. The negative regulation of cell interactions with the extracellular matrix could be the way PTEN phosphatase acts as a tumor suppressor. PTEN gene plays an essential role in human development. A recent model sees PTEN function as a stepwise gradation, which can be impaired not only by heterozygous mutations and homozygous losses, but also by other molecular mechanisms, such as transcriptional regression, epigenetic silencing, regulation by microRNAs, posttranslational modification, and aberrant localization.
    [Show full text]
  • Transcriptome Sequencing and Genome-Wide Association Analyses Reveal Lysosomal Function and Actin Cytoskeleton Remodeling in Schizophrenia and Bipolar Disorder
    Molecular Psychiatry (2015) 20, 563–572 © 2015 Macmillan Publishers Limited All rights reserved 1359-4184/15 www.nature.com/mp ORIGINAL ARTICLE Transcriptome sequencing and genome-wide association analyses reveal lysosomal function and actin cytoskeleton remodeling in schizophrenia and bipolar disorder Z Zhao1,6,JXu2,6, J Chen3,6, S Kim4, M Reimers3, S-A Bacanu3,HYu1, C Liu5, J Sun1, Q Wang1, P Jia1,FXu2, Y Zhang2, KS Kendler3, Z Peng2 and X Chen3 Schizophrenia (SCZ) and bipolar disorder (BPD) are severe mental disorders with high heritability. Clinicians have long noticed the similarities of clinic symptoms between these disorders. In recent years, accumulating evidence indicates some shared genetic liabilities. However, what is shared remains elusive. In this study, we conducted whole transcriptome analysis of post-mortem brain tissues (cingulate cortex) from SCZ, BPD and control subjects, and identified differentially expressed genes in these disorders. We found 105 and 153 genes differentially expressed in SCZ and BPD, respectively. By comparing the t-test scores, we found that many of the genes differentially expressed in SCZ and BPD are concordant in their expression level (q ⩽ 0.01, 53 genes; q ⩽ 0.05, 213 genes; q ⩽ 0.1, 885 genes). Using genome-wide association data from the Psychiatric Genomics Consortium, we found that these differentially and concordantly expressed genes were enriched in association signals for both SCZ (Po10 − 7) and BPD (P = 0.029). To our knowledge, this is the first time that a substantially large number of genes show concordant expression and association for both SCZ and BPD. Pathway analyses of these genes indicated that they are involved in the lysosome, Fc gamma receptor-mediated phagocytosis, regulation of actin cytoskeleton pathways, along with several cancer pathways.
    [Show full text]
  • Michael S. Brown, MD
    DISTINGUISHED PHYSICIANS AND Michael S. Brown, M.D. Sir Richard Roberts, Ph.D. Winner, 1985 Nobel Prize in Physiology or Medicine Winner, 1993 Nobel Prize in Physiology or Medicine MEDICAL SCIENTISTS MENTORING Winner, 1988 Presidential National Medal of Science A globally prominent biochemist and molecular biologist, DELEGATES HAVE INCLUDED... Dr. Brown received the world’s most prestigious medical Dr. Roberts was awarded the Nobel Prize for his prize for his work describing the regulation of the groundbreaking contribution to discovering RNA splicing. cholesterol metabolism. His work laid the foundation for Dr. Roberts is dedicating his future research to GMO crops the class of drugs now called statins taken daily by more than 20 million and food sources, and demonstrating the effect they have on humanity. — GRANDg MASTERS — people worldwide. Ferid Murad, M.D., Ph.D. Mario Capecchi, Ph.D. Boris D. Lushniak, M.D., M.P.H Winner, 1998 Nobel Prize in Physiology or Medicine Academy Science Director The Surgeon General of the United States (acting, 2013-2014) Winner, 2007 Nobel Prize in Physiology or Medicine A world-renowned pioneer in biochemistry, Dr. Murad’s Winner, 2001 National Medal of Science Rear Admiral Lushniak, M.D., M.P.H., was the United award-winning research demonstrated that nitroglycerin Winner, 2001 Lasker Award States’ leading spokesperson on matters of public health, and related drugs help patients with heart conditions by Winner, 2003 Wolf Prize in Medicine overseeing the operations of the U.S. Public Health Service releasing nitric oxide into the body, thus relaxing smooth Mario Capecchi, Ph.D., a biophysicist, is a Distinguished Commissioned Corps, which consists of approximately muscles by elevating intracellular cyclic GMP, leading to vasodilation and Professor of Human Genetics at the University of Utah School of Medicine.
    [Show full text]